NalP: Difference between revisions

From Proteopedia
Jump to navigation Jump to search
No edit summary
Michal Harel (talk | contribs)
No edit summary
 
(36 intermediate revisions by 5 users not shown)
Line 1: Line 1:
<Structure load='1UYN' size='350' frame='true' align='right' caption='Methotrexate' scene='Insert optional scene name here' />
<StructureSection load='1uyn' size='350' side='right' scene='' caption='Translocator domain of autotransporter NALP complex with pentaethylene glycol mpnpdecyl ether and sulfate, [[1uyn]]' pspeed='8'>


The '''Translocator Domain''' for the '''Autotransporter NaIP''' within ''Neisseria meningitidis'' provides a novel protein pore that contains an alpha helix running axially through its hydrophilic center. Classically many outer membrane pores contain a <scene name='Translocator_Domain_of_the_Autotransporter_NalP_within_Neisseria_meningitidis/Naip_-_beta_sheet/1'>12-member beta barrel</scene>, which is able to allow for different conditions than the peptidoglycan layer, which would typically stop many types of proteins and ions from passing through. This <scene name='Translocator_Domain_of_the_Autotransporter_NalP_within_Neisseria_meningitidis/Alpha_helix/1'>alpha helix </scene> blocks the pore from being totally open and allows for more regulation of what enters and leaves the cell.<ref name="NaIP"> Oomen, Clasien J., Patrick Van Gelder, Peter Van Ulsen, Maya Feijen, Jan Tommassen, and Piet Gros. "Structure of the Translocator Domain of a Bacterial Autotransporter." Www.ncbi.nlm.nih.gov. The EMBO Journal, 11 Mar. 2004. Web. 6 Nov. 2012. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC381419/>.</ref>


==Chemical Properties==
Chemical Formula: C<sub>20</sub>H<sub>22</sub>N<sub>8</sub>O<sub>5</sub>
Molecular Weight: 454.44 g/mol
Half-life: 3–15 hours<ref>Medical Pharmacology Topics. (n.d.). Angelfire: Welcome to Angelfire. Retrieved March 10, 2011, from http://www.angelfire.com/sc3/toxchick/medpharm/medpharm65.html</ref>
__TOC__
__TOC__






== ''Neisseria meningitides'' ==


== History ==
''Neisseria meningitides'' is a bacterium that infects humans and is the leading cause of “Meningitis (inflammation of the membranes surrounding the brain and spinal cord) is a common form of meningococcal disease and is characterized by fever, severe headache, and stiff neck. Patients with meningococcal sepsis (severe illness caused by bacteria or their toxins in the blood) may present with high fever, hypotension (low blood pressure), and profound weakness. In either case, patients may develop a characteristic rash including petechiae (pinpoint red spots that do not blanch with pressure) or purpura (purple areas similar to bruises) that are caused by bleeding into the skin. Purpura fulminans (hemorrhagic condition resulting in tissue necrosis and small vessel thrombosis) can result in scarring or limb amputations. Approximately 10-14% of cases of meningococcal disease are fatal. Of patients who recover, 11-19% have permanent hearing loss, mental retardation, loss of limbs or other severe sequelae." <ref>"Neisseria Meningitidis." Neisseria Meningitidis. Georgia Department of Public Health, n.d. Web. 13 Nov. 2012. <http://health.state.ga.us/epi/bacterial/path-neisseria.asp>.</ref> For this reason major amounts of research is being done on this bacteria and its transport mechanisms.
 
Methotrexate has provided as a treatment option in clinical setting since the year 1948.  Leukemia patients whom received folic acid, were observed to decline, while patients with restricted folic acid consumption improved, prompting experiments with analogs of folic acids.  Methotrexate was originally developed from these observations suggesting that an analog of folic acid was able to cause a remission in symptoms of acute lymphoblastic leukemia in 1947.  The subsequent derivation of a mechanism of action for methotrexate was developed and methotrexate was used for treatment of various cancerous even non-cancerous cases<ref>Methotrexate. (n.d.). UW Department of Orthopaedics and Sports Medicine - Patient Care. Retrieved March 10, 2011, from http://www.orthop.washington.edu/PatientCare/OurServices/Arthritis/Articles/Methotrexate.aspx </ref>.
 
 
<Structure load='2w3m' size='400' frame='true' align='right' caption='Human DHFR complexed with NADPH and folate' scene='Insert optional scene name here' />
 
== Structural Features DHFR==
 
Human DHFR can be visualized as an <scene name='Sandbox_58/Asymmetric_unit/1'>asymmetric unit</scene> as well as its <scene name='Sandbox_58/Biological_unit/1'>biological unit</scene>. DHFR contains 4 alpha helical regions and 8 beta sheets as can be seen in its <scene name='Sandbox_58/Secondary_structure_2w3m/1'>secondary structure</scene>. The <scene name='Sandbox_58/Acidic_basic/1'>acidic and basic residues</scene> can also be seen.  Human DHFR catalyzes the reduction of dihydrofolic acid to tetrahydrofolic acid, with NADPH serving as the electron donor in this reaction.  The <scene name='Sandbox_58/Active_site_2w3m-/1'>active site</scene> can be seen with the residues that facilitate substrate binding and reaction process.  The red residues represent the active site amino acid side chains interacting with the substrate, and the blue amino acid side chains help bind NADPH, with both folate and NADPH represented in white. <scene name='Sandbox_58/Active_site_2w3m-/2'>NADPH and folate</scene> can both be seen interacting with the DHFR enzyme (folate surrounded by red sidechains, and NADPH surrounded by blue sidechains)<ref>Schnell JR, Dyson HJ, Wright PE (June 2004). "Structure, dynamics, and catalytic function of dihydrofolate reductase.". Annual Review of Biophysics and Biomolecular Structure 33: 119–40</ref>.
 
[[Image:2011-03-10_0221.png|500|left|thumb| NADPH Residue Interaction ]]<ref>DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE. (n.d.). RCSB Protein Database. Retrieved March 10, 2011, from www.rcsb.org/pdb/results </ref>[[Image:2011-03-10_0222.png|500|center|thumb| Folate Residue Interaction ]]
<ref>DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE. (n.d.). RCSB Protein Database. Retrieved March 10, 2011, from www.rcsb.org/pdb/results </ref>
 
[[Image:thymidinesynthesis.jpg|left|thumb| Thymidine Synthesis Mechanism ]] <ref>DNA Synthesis - Replication: Chromatin Structure. (n.d.). The Medical Biochemistry Page. Retrieved March 10, 2011, from http://themedicalbiochemistrypage.org/dna.html </ref>
 
 
 
 
 
 
 
 
 


==Structure==
==Structure==
Line 42: Line 15:
===Beta Barrel===
===Beta Barrel===


The unique structure that makes this pore is able to allow for transportation in and out of the gram-negative cell is what is called a beta barrel. This beta barrel is created with 12 anti-parellel beta-pleated sheets that have wrapped around creating anti-parellel interaction between sheet one and sheet 12. This creates a tube structure that transcends through the membrane of a cell creating a new environment that allows for polar molecules to move through the cell membrane and cell wall when they would have otherwise been stopped by the hydrophobic center of peptidoglycan. The start and end of the beta barrel is on the periplasm side of the membrane and after a short tight turn T0 becomes the alpha-helix which has its n-terminus side facing outward toward extracellular material.
The beta barrel is a unique structure that makes this pore able to allow for transportation in and out of the gram-negative cell. This beta barrel is created with 12 anti-parallel beta-pleated sheets that have wrapped around creating anti-parellel interaction between sheet 1 and sheet 12. This creates a tube structure that transcends through the membrane of a cell creating a new environment that allows for polar molecules to move through the cell membrane and cell wall when they would have otherwise been stopped by the hydrophobic center of peptidoglycan. The start and end of the beta barrel is on the periplasmic side of the membrane and a short tight turn, <scene name='Translocator_Domain_of_the_Autotransporter_NalP_within_Neisseria_meningitidis/T0/1'>T0</scene>, connects the alpha helix to the N-terminal beta strand.  The alpha helix has its N-terminus side facing outward toward extracellular material. <ref name="PMID: 8254661"> PMID: 8254661 </ref>
 


=== Alpha Helix ===
=== Alpha Helix ===


The Alpha Helix within the Beta Barrel is a major obstruction which allows for regulated channel. The Alpha Helix corresponds to the .15nS opening that is observed and without this obstruction a 1.3nS open pore is created which allows for a much more free flowing pore. This is found to be infrequent occurrence which could be caused by a detergent and high salt concentration. Due to this being the more infrequent type of pore it is able to be deduced that the internal alpha helix is what is found in vivo. The alpha helix is found internally on the N-terminus side of the protein and extends from n-terminus facing the extracellular space leading inward toward the cytoplasm which turns then into a beta pleated sheet that creates the barrel shape. The alpha helix is charged almost solely on one side. This charged side is able to interact with an axial line of charged side chains that point inward from the beta barrel. Through seven salt bridges as well as through 16 hydrogen bonds and van der Waals contacts the alpha helix is able to interact with one side of the beta barrel.
The alpha helix within the beta barrel is a major obstruction, which allows for regulated channel. The alpha helix corresponds to the .15nS opening that is observed and without this obstruction a 1.3nS open pore is created which allows for a much more free flowing pore. This is found to be an infrequent occurrence that could be caused by a detergent and high salt concentration. Due to this being the more infrequent type of pore it can be deduced that the internal alpha helix is what is found in vivo. The alpha helix is found internally on the N-terminus side of the protein and extends from <scene name='Translocator_Domain_of_the_Autotransporter_NalP_within_Neisseria_meningitidis/N-terminus/1'>N-terminus facing the extracellular space</scene>, colored orange, leading inward toward the cytoplasm that then turns into a beta pleated sheet that creates the barrel shape. This structure is consistent with the final stage of translocation, which allows for proteins to be released into the extracellular space. The alpha helix is charged almost solely on one side. This charged side of the alpha helix is able to interact with an axial line of charged side chains that point inward from the beta barrel. Through seven salt bridges, as well as 16 hydrogen bonds and several van der Waals contacts, the alpha helix is able to interact with one side of the beta barrel.<ref name="PMID: 8254661" />




== Function of Alpha Helix==
== Function of Alpha Helix==


In order to test the function of the alpha helix within the domain a test was done in order to compare results of uptake within the domain with alpha helix and without the helix. An easy way to test this was a antibiotic assay. By isolating colonies strictly of gram negative bacteria with the alpha helix, NalPβ, and isolating colonies strictly of gram negative bacteria without the alpha helix, NalPβΔhelix, they could plate these separately. From there it was possible to compare susceptibility to antibiotics by placing the small circular tabs of antibiotics on the plate and measuring the difference in how effect the antibiotics was in penetrating the cell. The more penetration would show less growth inhibition or more sensitivity to the antibiotics. When the alpha helix was removed there was much more sensitivity to antibiotics showing that the removal of it leads to a more open pore.
In order to test the function of the alpha helix within the domain, a test was done in order to compare results of uptake within the domain in the presence of the alpha helix and without the alpha helix. An easy way to test this was an antibiotic assay. By isolating colonies strictly of gram-negative bacteria with the alpha helix, NalPβ, and isolating colonies strictly of gram-negative bacteria without the alpha helix, NalPβΔhelix, and then plating these separately. From this, it was possible to compare susceptibility to antibiotics by placing the small circular tabs of antibiotics on the plate and measuring the difference in how effective the antibiotics were in penetrating the cell. More penetration means less growth inhibition or more sensitivity to the antibiotics. When the alpha helix was removed there was much more sensitivity to antibiotics showing that the removal leads to a more open pore.<ref name="NaIP" />
 
 
== Mechanism of Action ==
 
 
 
 
 
<Structure load='2w3m' size='500' frame='true' align='right' caption='Human DHFR' scene='Insert optional scene name here' />
Methotrexate, is an antifolate which plays an inhibiting role in the synthesis of thymidylate through the prevention of THF regeneration. Methotrexate is a slow and tight binding competitive inhibitor of <scene name='Sandbox_58/Dhfr/1'>DHFR</scene>, resulting in the prevention of important metabolites necessary in thymidylate synthesis and nucleotide metabolism. Specifically, methotrexate acts as a DHF analog and through competitive inhibition of the DHFR active site, prevents the regeneration reaction necessary for further nucleotide biosynthesis.  Methotrexate’s antimetabolite function seen in the competitive inhibition mechanism affects the metabolism of folic acid.  Methotrexate is phase specific to the S phase of the cell cycle inhibiting DNA synthesis and replication within the afflicted cell.  Competitive inhibition of the DHFR active site is possible because of the close resemblance that methotrexate shares with the metabolite being interfered with, dihydrofolate<ref>Rajagopalan, P. T. Ravi; Zhang, Zhiquan; McCourt, Lynn (2002). "Interaction of dihydrofolate reductase with methotrexate: Ensemble and single-molecule kinetics". Proceedings of the National Academy of Sciences 99 (21): 13481–6.</ref>.
 
 
[[Image:Methotrexate and folic acid compared.png|folic acid                methotrexate]]<ref>Methotrexate and Folic Acid. (2006, September 3). Wikimedia Commons. Retrieved March 10, 2011, from commons.wikimedia.org/.png </ref>
 
Folic Acid (left)                          Methotrexate (right)
 
 
The nature of this binding has a 1000 fold increase in affinity relative to the natural folate affinity of DHFR , producing a practically irreversible inhibition of <scene name='Sandbox_58/N_to_c/1'>DHFR</scene> activity, (blue = N-terminal, red C-terminal).  Methotrexate is a competitive inhibitor that can bind to and inhibit the <scene name='Sandbox_58/Dhf_reductase/1'>DHRF active site</scene>, residues displayed in red, and the flexible Met20 loop surrounding the active site displayed in blue. Specifically, methotrexate is able to competitively interact</scene> with the <scene name='Sandbox_58/Active_site_mxt/2'>active site </scene> residues of DHFR, specifically Asp27, Phe31, Arg57, and Tyr100, with associations with the Asn18, Leu28, and Ile50 residues. The active site is buried within the enzyme as is depicted by the <scene name='Sandbox_58/Solvent_accessable_surface/1'>solvent accessable surface</scene> shown in orange at the entrance to the active site.  The
<scene name='Sandbox_58/Relative_temperature/1'>relative temperature</scene> are color depictions of each atom in regards to mobility or position uncertainty relative to the molecule, with increasing mobility as the color scheme goes from blue to red.  The interactions of the rest of the protein are depicted through the <scene name='Sandbox_58/H_bonds/1'>hydrogen bonds</scene> displayed in red<ref>Matthews DA, Alden RA, Bolin JT, Freer ST, Hamlin R, Xuong N, Kraut J, Poe M, Williams M, Hoogsteen K (July 1977). "Dihydrofolate reductase: x-ray structure of the binary complex with methotrexate". Science 197 (4302): 452–455.</ref>.
 
[[Image:2011-03-10_0224.png|500|left|thumb| Methotrexate Residue Interaction ]]<ref>DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE. (n.d.). RCSB Protein Database. Retrieved March 10, 2011, from www.rcsb.org/pdb/results </ref>[[Image:DHFR ligands.png|500|center|thumb| DHFR substrates ]]<ref>Enzymes. (n.d.). Oregon State University. Retrieved March 10, 2011, from http://oregonstate.edu/instruction/bb450/fall2010/lecture/enzymesoutline.html </ref>
 
 
== Experimental Mutation ==
 
<Structure load='3eig' size='500' frame='true' align='right' caption='DHFR methotrexate' scene='Insert optional scene name here' />
 
The features of DHFR ligand binding, specifically to methotrexate can be observed and analyzed through various molecular docking and mutation experiments.  The a structurally engineered variant of the <scene name='Sandbox_58/Arg_31-35_norm/1'>native human DHFR</scene> altered the F 31 residue of the protein to R, and the Q 35 residue of the protein to E in an attempt to explore the specifics of the methotrexate affinity for DHFR active site residues, resulting in varied active site residues from phenylalanine and glutamine to <scene name='Sandbox_58/Arg_31_glutamine_35/1'>arginine and glutamate</scene>.  This mutated enzyme featured a 650x decrease in affinity for the ligand, methotrexate, but retained an amount of methotrexate interaction similar to the enzyme in its native state with native substrates.  Crystal structure analysis revealed that the lack of cooperative action and presence of residue disorder lead to the significant decrease in methotrexate activity with the resulting <scene name='Sandbox_58/3eig_active_site/1'>active site</scene>.  The arginine residue at place 31, was specifically observed in numerous conformations, a characteristic unique to the mutated enzyme, and the probable cause of the loss of polar contacts and binding affinity between methotrexate and DHFR.  A loss of van der Waal forces due to the conformations of the side chains along with an unfavorable placement of Glu-35 causing an “unfavorable electrostatic contact” with methotrexate’s “glutamate portion.”  Interestingly this variant was found to display a greater decrease in methotrexate affinity than the decrease in affinity of Dihydrofolate, found to be 9x, evident of catalytic efficiency retention which hold many drug binding resistance implications<ref>Volpato, J., Yachnin, B., & Blanchet, J. (2009). Multiple conformers in active site of human dihydrofolate reductase F31R/Q35E double mutant suggest structural basis for methotrexate resistance.. Journal Biol. Chem., 284, 20079-20089. </ref>.
[[Image:2011-03-10 2241.png|500|left|thumb| Methotrexate Variant Residue Interaction ]]<ref>DIHYDROFOLATE REDUCTASE COMPLEXED WITH METHOTREXATE. (n.d.). RCSB Protein Database. Retrieved March 10, 2011, from www.rcsb.org/pdb/results </ref>
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 




== Integration of the Translocator Domain into Outer Membrane ==


Omp85 has been found in many studies to help integrate beta barrels into the outer membrane in order to allow the autotransporter to complete its duty. Due to the <scene name='Translocator_Domain_of_the_Autotransporter_NalP_within_Neisseria_meningitidis/Hydophilic/1'>hydrophilic nature</scene> of the beta barrel’s hairpin loops on the extracellular side of NaIP, it is impossible for it to breach the cell membrane that is highly hydrophobic. Research on how this occurs in Neisseria meningitides is ongoing and has not been discovered yet. Yet there are many implications that a protein named Omp85 is most likely the helper protein that facilitates this. The large hydrophilic loops on the autotransporter domain might act as a recognition signal for the Omp85 complex to encompass the end of the beta barrel. From here the Omp85 complex which sits on the periplasmic side of the cell membrane is activated and creates a pore and places the beta barrel within the membrane, while preventing the hydrophilic loops from directly coming in contact with the hydrophobic cell membrane. Then the Omp85 molecule is able to integrate the beta barrel into the pore that it created, situating it permanently there. The lag time between Omp85 and the translocator exporting a protein is very small and it is hard to tell whether they can occur simultaneously or only occur simultaneously. <ref name="PMID: 8254661" />




== Protein Transportation Mechanism ==


== Pharmaceutical Implications ==
[[Image: Loop Structures.jpg | thumb | alt=text | Picture 1]]


Methotrexate’s inhibition of cellular replication causes it to have an increased toxic response on cells performing DNA replication especially rapidly proliferating cells.  These cells display decreased growth and division due to a lack of nucleoside biosynthesis metabolites, resulting in decreased dTMP.  Methotrexate is able to interfere with rapid cell growth in this manner, specifically infecting cells including skin cells, bone marrow cells, and often cancer cells, making methotrexate an effective cancer treatment drug. Other DHF analogs exist which can be useful as anticancer agents or antibacterial agents, through inhibition of DHFR
<ref>Methotrexate Information from Drugs.com. (n.d.). Drugs.com | Prescription Drugs - Information, Interactions & Side Effects. Retrieved March 10, 2011, from http://www.drugs.com/methotrexate.html</ref>.


Interesting questions were raised on how the alpha helix in the center of the beta barrel affected the mechanism of protein transportation out of the cell. The first step to understanding what shapes of proteins can move though the pore was figured out by trying to move a disulfide bond through the pore. This was unsuccessful and led to part of the understanding that the only way that proteins can move though this pore was by being completely unfolded. Yet once inside of the extracellular material, the protein must be folded. Knowing these two crucial pieces of data, it was clear that as the protein passes through the pore it must make a transition from unfolded to folded. Due to the C-terminal end's placement on the periplasmic side of the pore it was highly unlikely that was the participating portion that effected the change in conformation of the protein as it passes through. Oppositely the N-terminal side of the pore lies on the alpha helix facing the extracellular matter, placing it in prime location to change the conformation of the passing protein. Another possible place where interaction could occur between the passing protein and the pore would be at a large hairpin loop that is on the extracellular side of the pore. This would also provide a prime placement for the initiation of protein folding.<ref name="NaIP" />


== Drug Treatment ==


Methotrexate is often used in a regimental approach to the chemotherapeutic treatment of cancers and other diseases involving replicating tissue.  A variety of specific cancer types have been treated with methotrexate including head, lung, skin, or breast cancer.  Methotrexate has also been used in the treatment of various autoimmune diseases. Rheumatoid arthritis and psoriasis have also utilized methotrexate as a treatment method, presumably to diminish immune function.  The mechanism of methotrexate in these instances varies from the inhibition of DHFR, but involves inhibition of enzymes involved with purine metabolism resulting in various types of immune suppression including inhibition of T cell activation.  Because of this altered mechanism, treated patients are often administered folate to offset the antifolate characteristics of methotrexate.  The targeting of rapidly replicating cells allows methotrexate to function as an abortifacient as well.  These uses of methotrexate need to be carefully monitored with proper dosage because methotrexate is embryotoxic, carcinogenic, and teratogenic<ref>Marks, J. W. (2008, January 8). Methotrexate. Medicine Net. Retrieved March 10, 2011, from www.medicinenet.com/methotrexate/article.htm </ref>.
=== Threading Model ===


Trexall is a drug, methotrexate tablet, used as an antimetabolite for treatment of neoplastic diseases, severe rheumatoid arthritis and psoriasis<ref>Trexall. (2007, November 20). The RX List. Retrieved March 10, 2011, from www.rxlist.com/trexall-drug.htm </ref>
The threading model could be one possible model that would allow for transportation of passenger proteins out of the cell and into extracellular material. The model has one single strand of protein entering and as it crosses to the other side it begins to fold starting with its N-terminus. The threading model is a possible explanation for how a protein would be able to fit through the narrow gap that the beta barrel and alpha helix provide. The threading model allows for one strand of the DNA to pass through the pore without being sterically hindered by the size of the alpha helix that blocks the beta barrel. Yet there are reasons why this is an unlikely model. One major reason why this seems implausible is that other research that has been done on autotransporters has shown that the last thing to leave the pore of the passenger protein is the N-terminus. So therefore how would the N-terminus start the folding if it is the last thing to leave? This also means that the autotransporter would have to secrete something in order to allow for the attraction of the N-terminus side to the pore. This was unable to be shown in artificial passenger proteins.<ref name="NaIP" />




== Treatment ==
=== Hairpin Model ===


Methotrexate can be administered orally as well as intravenous, intramuscular, subcutaneous, or intrathecal injection.  Dosage amount is a crucial aspect of any methyltrexate treatment because of the serious side affects, and often results in dosages being taken rarely more than once or twice a week. The immune system, blood cells, and other rapidly replicating cells including liver, lungs, kidneys are often succeptable to damage which requires regular tests. Side effects from this drug can be common and sever including neutropenia, hair loss, nausea, dermatitis, and anemia, often representative of the antimetabolite function of methotrexate. Stomatitis is not commonly seen with weekly doses, but daily doses for 5 consecutive days often results in these symptoms including renal impairment, toxicity, and possible failure. Myelosuppression may develop with increased dosages, enhancing tissue damage resulting most commonly from radiation of cancer patients. Additional drugs including antibiotics can often result in adverse side effects, and increased methotrexate retention due to additional drugs can often lead to a dangerous increase in concentration of methotrexate in the blood
The Hairpin Model is a much more likely model that could accommodate for the movement across the membrane. The hairpin model allows for a hairpin loop to be created in the passenger protein and as it passes through the end of the pore a hairpin loop there interacts with the passenger protein in order to create the folding. As the protein is folded it provides energy to pull the rest of the protein through. One major problem with this model is the fact that 2 strands must fit through the protein at once and with the alpha helix that is an impossible fit. The model describes a fix to this problem with the destruction of the alpha helix and recreation. When the alpha helix is nonexistent the hydrogens that typically face inward and interact with the alpha helix face toward one another or even outward which expands the barrel as well as making it much more flexible. This model suggests that folding and translocation are interdependent and happen simultaneously. The problem with this method is there is no mechanism for how the alpha helix is created or dismantled and where it goes.<ref name="NaIP" />
<ref>Schwartza, S., & Borner, K. (2007). Glucarpidase (Carboxypeptidase G2) Intervention in Adult and Elderly Cancer Patients with Renal Dysfunction and Delayed Methotrexate Elimination After High-Dose Methotrexate Therapy. The Oncologist, 12(11), 1299-1308.</ref>.


The nature of this treatment type can requires the “rescue” of a patient, through withdrawal of the inhibitor and possible administering of thymidine or folic acid based drugs to prevent the toxicity sometimes seen in beneficial rapidly replicating cells. Leucovorin is often administered for this rescuing effect.  Leucovorin or folinic acid is a derivative of THF, and can be readily converted to tetrahydrofolate overcoming the effect of methotrexate because it bypasses the dihydrofolate reductase mechanism to produce THF<ref>Sirotnak, F., Dorick, D., & Moccio, D. (1978). Murine Tumor ModelsRescue Therapy in the L1210 Leukemia and Sarcoma 180 Optimization of High-Dose Methotrexate with Leucovorin . CANCER RESEARCH, 38, 345-353. Retrieved March 10, 2011, from cancerres.aacrjournals.org/content/38/2/345.full.pdf </ref>.


=== Alternative Theory ===


== Pharmacokinetics ==
One alternative theory argues that the beta barrel is actually not used as a protein secretion pore at all. As Omp85 encompasses the end of the beta barrel it travels toward the cell membrane as if to place the autotransporter into the cell membrane yet instead of placing it, Omp85 continues through into the extracellular material. As the translocator is being carried toward the cell membrane it is able to pick up a passenger protein using its loose C-terminus end that would have faced inward toward the perIplasm. Then all three the, the Omp85, the translocator, and the passenger protein, are transported to extracellular material through the pore that Omp85 is able to create. Then they all dissociate away from one another, which frees the passenger protein. This is another possibility for how the translocator is able to transport passenger protein out of the cell yet changes the view of the translocator all-together. If this is in fact the way that passenger proteins leave the cell then NaIP is not an autotransporter at all. An autotransporter, just as it sounds, autotransports, meaning that the protein pulls itself through as it is folded on the opposite side of the cell. As plausible as this seems, it would mean a major change in the way that this translocator protein is classified. <ref name="NaIP" />


Dosage size of methotrexate is extremely important because of the antimetabolic function of the drug, therefore many pharmacokinetic properties must be considered prior to treatment.  Methotrexate is a dicarboxylic acid, although with a pKa of 4.8 and 5.5 is weak and often ionized in physiological conditions.  Bioavailability following oral absorption is dose dependent, with 60 percent at doses lower than 30 mg/m2, and at concentrations above 80 mg/m2, there is only 20 percent bioavailability, percentages that can be increased with intramuscular administering of the drug.  Only about 5 percent of the total loss of the oral dose is due to bacterial degradation.  The kidney, spleen, liver, gallbladder, as well as the skin display the highest levels of methotrexate upon treatment.  This drug does not cross the blood brain barrier efficiently, but the distribution to the kidney and liver may be prolonged with higher doses extending drug clearance time.  Methotrexate can be metabolized through the liver and intracellular mechanisms, and the kidneys are capable of excreting from 80 to 90 percent of the drug without metabolizing methotrexate<ref>Methotrexate. (2010, September 1). CCO Formulary. Retrieved March 10, 2011, from www.cancercare.on.ca/pdfdrugs/methotre.pdf </ref>.


==Additional Information==
== Similar Structure in Other Proteins ==
For additional information see: [[Pharmaceutical Drugs]]


== References ==
Recent research has showed that there are possible conserved features to this pore and pores in other types of gram-negative bacteria. Autotransporters that also have the conserved structure of an alpha helix directly preceding the beta core include: AidaI of E. coli, BrkA of B. pertussis, Hap of Hemophilus influenzae and IgA protease and App of N. meningitidis. Much of the these proteins show low conservation within their alpha helixes yet they all have a long traversing alpha helix that leads into the 12 sheeted beta barrel. Due to the amount of research being done on the Neisseria meningitidis' NalPβ protein, its crystal structure is being used in order to model autotransporter secretion. <ref name="NaIP" />
</StructureSection>
== 3D structure of NalP ==


<references/>
[[1uyn]], [[1uyo]] - NalP - ''Neisseria meningitides'' <br />
==References==
<references />
[[Category:Topic Page]]

Latest revision as of 20:57, 20 October 2017


The Translocator Domain for the Autotransporter NaIP within Neisseria meningitidis provides a novel protein pore that contains an alpha helix running axially through its hydrophilic center. Classically many outer membrane pores contain a , which is able to allow for different conditions than the peptidoglycan layer, which would typically stop many types of proteins and ions from passing through. This blocks the pore from being totally open and allows for more regulation of what enters and leaves the cell.[1]


Neisseria meningitides

Neisseria meningitides is a bacterium that infects humans and is the leading cause of “Meningitis (inflammation of the membranes surrounding the brain and spinal cord) is a common form of meningococcal disease and is characterized by fever, severe headache, and stiff neck. Patients with meningococcal sepsis (severe illness caused by bacteria or their toxins in the blood) may present with high fever, hypotension (low blood pressure), and profound weakness. In either case, patients may develop a characteristic rash including petechiae (pinpoint red spots that do not blanch with pressure) or purpura (purple areas similar to bruises) that are caused by bleeding into the skin. Purpura fulminans (hemorrhagic condition resulting in tissue necrosis and small vessel thrombosis) can result in scarring or limb amputations. Approximately 10-14% of cases of meningococcal disease are fatal. Of patients who recover, 11-19% have permanent hearing loss, mental retardation, loss of limbs or other severe sequelae." [2] For this reason major amounts of research is being done on this bacteria and its transport mechanisms.

Structure

Beta Barrel

The beta barrel is a unique structure that makes this pore able to allow for transportation in and out of the gram-negative cell. This beta barrel is created with 12 anti-parallel beta-pleated sheets that have wrapped around creating anti-parellel interaction between sheet 1 and sheet 12. This creates a tube structure that transcends through the membrane of a cell creating a new environment that allows for polar molecules to move through the cell membrane and cell wall when they would have otherwise been stopped by the hydrophobic center of peptidoglycan. The start and end of the beta barrel is on the periplasmic side of the membrane and a short tight turn, , connects the alpha helix to the N-terminal beta strand. The alpha helix has its N-terminus side facing outward toward extracellular material. [3]


Alpha Helix

The alpha helix within the beta barrel is a major obstruction, which allows for regulated channel. The alpha helix corresponds to the .15nS opening that is observed and without this obstruction a 1.3nS open pore is created which allows for a much more free flowing pore. This is found to be an infrequent occurrence that could be caused by a detergent and high salt concentration. Due to this being the more infrequent type of pore it can be deduced that the internal alpha helix is what is found in vivo. The alpha helix is found internally on the N-terminus side of the protein and extends from , colored orange, leading inward toward the cytoplasm that then turns into a beta pleated sheet that creates the barrel shape. This structure is consistent with the final stage of translocation, which allows for proteins to be released into the extracellular space. The alpha helix is charged almost solely on one side. This charged side of the alpha helix is able to interact with an axial line of charged side chains that point inward from the beta barrel. Through seven salt bridges, as well as 16 hydrogen bonds and several van der Waals contacts, the alpha helix is able to interact with one side of the beta barrel.[3]


Function of Alpha Helix

In order to test the function of the alpha helix within the domain, a test was done in order to compare results of uptake within the domain in the presence of the alpha helix and without the alpha helix. An easy way to test this was an antibiotic assay. By isolating colonies strictly of gram-negative bacteria with the alpha helix, NalPβ, and isolating colonies strictly of gram-negative bacteria without the alpha helix, NalPβΔhelix, and then plating these separately. From this, it was possible to compare susceptibility to antibiotics by placing the small circular tabs of antibiotics on the plate and measuring the difference in how effective the antibiotics were in penetrating the cell. More penetration means less growth inhibition or more sensitivity to the antibiotics. When the alpha helix was removed there was much more sensitivity to antibiotics showing that the removal leads to a more open pore.[1]


Integration of the Translocator Domain into Outer Membrane

Omp85 has been found in many studies to help integrate beta barrels into the outer membrane in order to allow the autotransporter to complete its duty. Due to the of the beta barrel’s hairpin loops on the extracellular side of NaIP, it is impossible for it to breach the cell membrane that is highly hydrophobic. Research on how this occurs in Neisseria meningitides is ongoing and has not been discovered yet. Yet there are many implications that a protein named Omp85 is most likely the helper protein that facilitates this. The large hydrophilic loops on the autotransporter domain might act as a recognition signal for the Omp85 complex to encompass the end of the beta barrel. From here the Omp85 complex which sits on the periplasmic side of the cell membrane is activated and creates a pore and places the beta barrel within the membrane, while preventing the hydrophilic loops from directly coming in contact with the hydrophobic cell membrane. Then the Omp85 molecule is able to integrate the beta barrel into the pore that it created, situating it permanently there. The lag time between Omp85 and the translocator exporting a protein is very small and it is hard to tell whether they can occur simultaneously or only occur simultaneously. [3]


Protein Transportation Mechanism

text
Picture 1


Interesting questions were raised on how the alpha helix in the center of the beta barrel affected the mechanism of protein transportation out of the cell. The first step to understanding what shapes of proteins can move though the pore was figured out by trying to move a disulfide bond through the pore. This was unsuccessful and led to part of the understanding that the only way that proteins can move though this pore was by being completely unfolded. Yet once inside of the extracellular material, the protein must be folded. Knowing these two crucial pieces of data, it was clear that as the protein passes through the pore it must make a transition from unfolded to folded. Due to the C-terminal end's placement on the periplasmic side of the pore it was highly unlikely that was the participating portion that effected the change in conformation of the protein as it passes through. Oppositely the N-terminal side of the pore lies on the alpha helix facing the extracellular matter, placing it in prime location to change the conformation of the passing protein. Another possible place where interaction could occur between the passing protein and the pore would be at a large hairpin loop that is on the extracellular side of the pore. This would also provide a prime placement for the initiation of protein folding.[1]


Threading Model

The threading model could be one possible model that would allow for transportation of passenger proteins out of the cell and into extracellular material. The model has one single strand of protein entering and as it crosses to the other side it begins to fold starting with its N-terminus. The threading model is a possible explanation for how a protein would be able to fit through the narrow gap that the beta barrel and alpha helix provide. The threading model allows for one strand of the DNA to pass through the pore without being sterically hindered by the size of the alpha helix that blocks the beta barrel. Yet there are reasons why this is an unlikely model. One major reason why this seems implausible is that other research that has been done on autotransporters has shown that the last thing to leave the pore of the passenger protein is the N-terminus. So therefore how would the N-terminus start the folding if it is the last thing to leave? This also means that the autotransporter would have to secrete something in order to allow for the attraction of the N-terminus side to the pore. This was unable to be shown in artificial passenger proteins.[1]


Hairpin Model

The Hairpin Model is a much more likely model that could accommodate for the movement across the membrane. The hairpin model allows for a hairpin loop to be created in the passenger protein and as it passes through the end of the pore a hairpin loop there interacts with the passenger protein in order to create the folding. As the protein is folded it provides energy to pull the rest of the protein through. One major problem with this model is the fact that 2 strands must fit through the protein at once and with the alpha helix that is an impossible fit. The model describes a fix to this problem with the destruction of the alpha helix and recreation. When the alpha helix is nonexistent the hydrogens that typically face inward and interact with the alpha helix face toward one another or even outward which expands the barrel as well as making it much more flexible. This model suggests that folding and translocation are interdependent and happen simultaneously. The problem with this method is there is no mechanism for how the alpha helix is created or dismantled and where it goes.[1]


Alternative Theory

One alternative theory argues that the beta barrel is actually not used as a protein secretion pore at all. As Omp85 encompasses the end of the beta barrel it travels toward the cell membrane as if to place the autotransporter into the cell membrane yet instead of placing it, Omp85 continues through into the extracellular material. As the translocator is being carried toward the cell membrane it is able to pick up a passenger protein using its loose C-terminus end that would have faced inward toward the perIplasm. Then all three the, the Omp85, the translocator, and the passenger protein, are transported to extracellular material through the pore that Omp85 is able to create. Then they all dissociate away from one another, which frees the passenger protein. This is another possibility for how the translocator is able to transport passenger protein out of the cell yet changes the view of the translocator all-together. If this is in fact the way that passenger proteins leave the cell then NaIP is not an autotransporter at all. An autotransporter, just as it sounds, autotransports, meaning that the protein pulls itself through as it is folded on the opposite side of the cell. As plausible as this seems, it would mean a major change in the way that this translocator protein is classified. [1]


Similar Structure in Other Proteins

Recent research has showed that there are possible conserved features to this pore and pores in other types of gram-negative bacteria. Autotransporters that also have the conserved structure of an alpha helix directly preceding the beta core include: AidaI of E. coli, BrkA of B. pertussis, Hap of Hemophilus influenzae and IgA protease and App of N. meningitidis. Much of the these proteins show low conservation within their alpha helixes yet they all have a long traversing alpha helix that leads into the 12 sheeted beta barrel. Due to the amount of research being done on the Neisseria meningitidis' NalPβ protein, its crystal structure is being used in order to model autotransporter secretion. [1]

Translocator domain of autotransporter NALP complex with pentaethylene glycol mpnpdecyl ether and sulfate, 1uyn

Drag the structure with the mouse to rotate

3D structure of NalP3D structure of NalP

1uyn, 1uyo - NalP - Neisseria meningitides

ReferencesReferences

  1. 1.0 1.1 1.2 1.3 1.4 1.5 1.6 Oomen, Clasien J., Patrick Van Gelder, Peter Van Ulsen, Maya Feijen, Jan Tommassen, and Piet Gros. "Structure of the Translocator Domain of a Bacterial Autotransporter." Www.ncbi.nlm.nih.gov. The EMBO Journal, 11 Mar. 2004. Web. 6 Nov. 2012. <http://www.ncbi.nlm.nih.gov/pmc/articles/PMC381419/>.
  2. "Neisseria Meningitidis." Neisseria Meningitidis. Georgia Department of Public Health, n.d. Web. 13 Nov. 2012. <http://health.state.ga.us/epi/bacterial/path-neisseria.asp>.
  3. 3.0 3.1 3.2 Klauser T, Kramer J, Otzelberger K, Pohlner J, Meyer TF. Characterization of the Neisseria Iga beta-core. The essential unit for outer membrane targeting and extracellular protein secretion. J Mol Biol. 1993 Dec 5;234(3):579-93. PMID:8254661 doi:http://dx.doi.org/S0022-2836(83)71613-X

Proteopedia Page Contributors and Editors (what is this?)Proteopedia Page Contributors and Editors (what is this?)

Chris Casey, Michal Harel, Jaime Prilusky, Alexander Berchansky, Joel L. Sussman